Loading
The protein that builds the microtubule scaffolding a cell needs to pull its chromosomes apart. Taxanes freeze the scaffold and vinca alkaloids and eribulin stop it forming; either way the dividing cell stalls and dies. This dossier gathers the 4 products (1 approved), 14 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Heterodimeric building block of microtubules; drug binding at the taxane, vinca or maytansine site disrupts spindle dynamics.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Housekeeping enzyme present in every dividing cell (microtubule scaffold for cell division); not a selection marker, which is why these drugs are given by cancer type rather than by test. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Withdrawn or failed |
|---|---|---|
| ADC 1 | - | |
| Chemotherapy 1 | - | |
| Small molecule 1 | - | |
| Vinca alkaloid, intravenous 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
INTELLANCE-1 NCT02573324 | 3 | Negative | Newly diagnosed glioblastoma with EGFR amplification: radiotherapy and temozolomide with depatuxizumab mafodotin or placebo | Depatuxizumab mafodotin added to radiotherapy and temozolomide did not improve overall survival in EGFR-amplified glioblastoma; stopped for futility. | |
| 3 | - | A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer | - | ||
| 3 | Completed | A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer | - | ||
SWOG 9916 NCT00004001 | 3 | Positive | Metastatic androgen-independent prostate cancer: estramustine 280 mg three times daily on days 1 to 5 with docetaxel 60 mg/m2 on day 2 and dexamethasone, against mitoxantrone 12 mg/m2 with prednisone, in 21-day cycles, with overall survival as the primary endpoint | Median overall survival 17.5 against 15.6 months (hazard ratio for death 0.80, 95 percent confidence interval 0.67 to 0.97, p=0.02) and time to progression 6.3 against 3.2 months, at the cost of more neutropenic fever, vomiting and cardiovascular events. | |
| 3 | Planned | A Multicenter, Open-Label, Randomized, Phase III Study Comparing UTD2 Combined With Capecitabine to Capecitabine Monotherapy as Adjuvant Therapy for Triple-Negative Breast Cancer Patients Who Did Not Achieve Pathological Complete Response | - | ||
| 3 | Recruiting | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | - | ||
| 3 | Completed | Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse | - | ||
| 3 | Completed | International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia | - | ||
| 3 | Active | B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents | - | ||
| 2 | Recruiting | A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases | - | ||
| 2 | Recruiting | The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study | - | ||
| 2 | Recruiting | Clinical Study of the Efficacy and Safety of Utidelone (UTD1) Combined With Capecitabine as Adjuvant Therapy in Non-pCR Triple-negative Breast Cancer Patients After Neoadjuvant Therapy | - | ||
| 2 | Planned | Phase II Clinical Trial on the Efficacy and Safety of Utidelone Combined with Bevacizumab in Patients with Non-small Cell Lung Cancer with Brain Metastases. | - | ||
| 1/2 | Active | Phase I-II Clinical Trial on Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Tubulin" OR ABSTRACT:"Tubulin" OR TITLE:"microtubules" OR ABSTRACT:"microtubules" OR TITLE:"TUBB" OR ABSTRACT:"TUBB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tubulin (microtubules), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/tubulin.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tubulin.json. Licence CC BY-NC 4.0.